This study focuses on patients with Pulmonary Arterial Hypertension (PAH), a condition that causes high blood pressure in the arteries of the lungs. The study will evaluate whether treatment with calcifediol, a form of vitamin D supplement, can improve the condition of patients who have very low vitamin D levels. The treatment will be compared to placebo to determine its effectiveness.
The study will test calcifediol given orally once every ten days for the first 12 weeks, followed by doses every two weeks for another 12 weeks. Two additional supplements will also be used in the study: triglycerides medium chain and alpha-tocopherol (a form of vitamin E). The total treatment period will last 24 weeks.
The main goal is to determine if this vitamin D supplementation leads to improvements in various aspects of the disease, including walking ability, heart function measurements, and overall risk level of the disease. The study will monitor how well patients tolerate the treatment and track any changes in their condition throughout the study period.
Spain 
